- Home
- LENZ vs RCUS Comparison
LENZ vs RCUS Comparison
Compare LENZ & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- RCUS
- Stock Information
- Founded
- LENZ 2019
- RCUS 2015
- Country
- LENZ United States
- RCUS United States
- Employees
- LENZ N/A
- RCUS N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- LENZ Health Care
- RCUS Health Care
- Exchange
- LENZ Nasdaq
- RCUS Nasdaq
- Market Cap
- LENZ 886.0M
- RCUS 906.4M
- IPO Year
- LENZ 2021
- RCUS 2018
- Fundamental
- Price
- LENZ $33.53
- RCUS $9.61
- Analyst Decision
- LENZ Strong Buy
- RCUS Buy
- Analyst Count
- LENZ 5
- RCUS 8
- Target Price
- LENZ $41.80
- RCUS $20.86
- AVG Volume (30 Days)
- LENZ 330.7K
- RCUS 891.1K
- Earning Date
- LENZ 05-07-2025
- RCUS 08-07-2025
- Dividend Yield
- LENZ N/A
- RCUS N/A
- EPS Growth
- LENZ N/A
- RCUS N/A
- EPS
- LENZ N/A
- RCUS N/A
- Revenue
- LENZ N/A
- RCUS $141,000,000.00
- Revenue This Year
- LENZ N/A
- RCUS N/A
- Revenue Next Year
- LENZ $544.90
- RCUS $28.73
- P/E Ratio
- LENZ N/A
- RCUS N/A
- Revenue Growth
- LENZ N/A
- RCUS N/A
- 52 Week Low
- LENZ $16.54
- RCUS $6.50
- 52 Week High
- LENZ $38.93
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- LENZ 54.45
- RCUS 53.46
- Support Level
- LENZ $32.72
- RCUS $9.14
- Resistance Level
- LENZ $35.87
- RCUS $9.62
- Average True Range (ATR)
- LENZ 1.97
- RCUS 0.44
- MACD
- LENZ -0.12
- RCUS 0.04
- Stochastic Oscillator
- LENZ 46.30
- RCUS 62.85
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.